Bli medlem
Bli medlem

Du är här

2014-05-15

AstraZeneca: Continuing progress in accelerating late stage pipeline reinforces confidence in AstraZeneca's strategy as an independent company

This week AstraZeneca demonstrated further evidence of continued
progress of its science-led strategy, as the company updated on new
data in advance of key medical and scientific congresses across all
of its core therapeutic areas - oncology, cardiovascular and
metabolic disease and respiratory, inflammation and autoimmunity.

Pascal Soriot, Chief Executive of AstraZeneca, said: "We continue to
build our pipeline and we are encouraged by the progress in the
development of key assets. We have complete confidence in our
strategy as an independent company and remain focused on delivering
new medicines for patients, which will continue to create significant
value for our shareholders."

AstraZeneca is targeting strong and consistent revenue growth leading
to annual revenues of greater than $45 billion by 2023, as outlined
in the 6th May financial update. [Link here]
(http://www.astrazeneca.com/Media/Press-releases/Article/20140506--astraz...)These
new data provide proof points for the progress being made on
AstraZeneca's pipeline across its core therapeutic areas.

Outlined below is a summary of the key data which will be presented at
upcoming medical and scientific conferences. Please see links to full
news releases.

Oncology

· MEDI4736 Phase I data demonstrated durable clinical activity and
acceptable safety for this investigational anti-PD-L1 antibody. [Link
here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140508--astraz...)]

· Data from the large Phase I study of AZD9291 suggest it is well
tolerated and clinically active in patients with EGFR mutation
positive (EGFRm+) non-small cell lung cancer (NSCLC) who have
developed acquired resistance to EGFR tyrosine-kinase inhibitors
(TKIs). [Link here]
(http://www.astrazeneca.com/Media/Press-releases/Article/20140514--astraz...)

· Encouraging efficacy data from a randomised Phase II study,
conducted by the US National Cancer Institute (NCI), investigating
the combination of PARP inhibitor olaparib and VEGF inhibitor
cediranib in high-grade serous ovarian cancer. [Link here]
(http://www.astrazeneca.com/Media/Press-releases/Article/20140514--astraz...)

· The first MedImmune oncology immunotherapy targeting the
PD-L1/PD-1 pathway progressed into Phase III. [Link here]
(http://www.astrazeneca.com/Media/Press-releases/Article/20140514--astraz...)

· MedImmune and Incyte announced collaboration on immuno-oncology
combination clinical trial. The Phase I/II oncology study will
evaluate the efficacy and safety of MedImmune's investigational
anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with
Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
[Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140514--medimm...)]

We believe that our rich oncology pipeline has the potential to
redefine the way that cancer patients are treated. We continue to
deliver on our late stage assets and drive our scientific leadership
in oncology, as clearly demonstrated by the recent accelerated
development of key assets.

Cardiovascular /Metabolic Disease

· Positive results from Phase III study of saxagliptin/dapagliflozin
combination in patients with type 2 diabetes inadequately controlled
on metformin and outlines future development plans for the oral
antidiabetic franchise. [Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140513--astraz...)]

· AstraZeneca will commence a Phase III trial for dapagliflozin in
patients with Type 1 diabetes in 2014.

Our metabolic disease area focuses on diabetes, diabetic nephropathy
and obesity. We plan to continue building our existing brands and
develop our research and clinical projects to meet patients' unique
medical needs and build a position of leadership.

Respiratory, Inflammation and Autoimmunity

· In collaboration with Amgen, Phase III study of brodalumab (AMG
827) in patients with moderate-to-severe plaque psoriasis met its
primary and secondary endpoints. [Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140509--az-and...)]

· Top-line results from the Phase IIb study of mavrilimumab, an
investigational monoclonal antibody that inhibits a key pathway in
the development of rheumatoid arthritis (RA), achieved its primary
endpoints. [Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140512--astraz...)]

· Top-line results from the Phase II study of sifalimumab
(MEDI-545), a novel monoclonal antibody being investigated as a
treatment for patients with moderate/severe systemic lupus
erythematosus (SLE or lupus). The study met its primary endpoint.
[Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140512--AstraZ...)]

· Phase IIb asthma data on benralizumab, an investigational
monoclonal antibody binding to the interleukin-5 receptor alpha
(IL-5Rα). Phase IIb data for tralokinumab, a human monoclonal
antibody which potently and selectively neutralises interleukin-13
(IL-13). Both showed improvement in key measures of asthma control
for patients with specific, severe forms of asthma. [Link here
(http://www.astrazeneca.com/Media/Press-releases/Article/20140512--AstraZ...)]

· AstraZeneca intends to move tralokinumab into Phase III
development for asthma and benralizumab into Phase IIl for COPD later
this year.

We continue to focus on building our strong position in the
respiratory area by delivering innovative, inhaled and targeted
therapies that address the evolving unmet medical needs of patients
with asthma COPD and idiopathic pulmonary fibrosis (IPF). In the
inflammatory and autoimmunity therapy areas, we intend to help
improve the lives of patients by developing a rheumatology franchise.

AstraZeneca will host a briefing for analysts and investors during the
American Thoracic Society (ATS) conference, to be held in San Diego
on 20 May 2014.

AstraZeneca will host a briefing for analysts and investors during the
American Society of Clinic Oncology (ASCO) conference, to be held in
Chicago on 2 June 2014.

- ENDS -

About MedImmune

MedImmune is the worldwide biologics research and development arm of
AstraZeneca. MedImmune is pioneering innovative research and
exploring novel pathways across key therapeutic areas, including
respiratory, inflammation and autoimmunity; cardiovascular and
metabolic disease; oncology; neuroscience; and infection and
vaccines. The MedImmune headquarters is located in Gaithersburg, Md.,
one of AstraZeneca's three global R&D centres. For more information,
please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Tracy Rossin +1 301 398-1468 (MedImmune)

Jacob Lund +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

The revenue target for 2023 set out in this announcement is derived
from the AstraZeneca Long Range Plan for 2014 to 2023 (the "LRP").
For further information regarding the LRP, attention is drawn to the
announcement regarding AstraZeneca's strategy on 6 May 2014 and the
key sources, bases and assumptions set out in that announcement.

Forward-Looking Statements

This announcement (including information incorporated by reference in
this announcement) and other information published by AstraZeneca
contain statements which are, or may be deemed to be,
"forward-looking statements", including for the purposes of the US
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are prospective in nature and are not based on historical
facts, but rather on current expectations and projections of the
management of AstraZeneca about future events, and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied by
the forward-looking statements. Often, but not always,
forward-looking statements can be identified by the use of
forward-looking words such as "plans", "expects" or "does not
expect", "is expected", "is subject to", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or statements that certain actions, events or results "may", "could",
"should", "would", "might" or "will" be taken, occur or be achieved.
Although AstraZeneca believes that the expectations reflected in such
forward-looking statements are reasonable, AstraZeneca can give no
assurance that such expectations will prove to be correct. By their
nature, forward-looking statements involve risk and uncertainty
because they relate to events and depend on circumstances that will
occur in the future. There are a number of factors that could cause
actual results and developments to differ materially from those
expressed or implied by such forward-looking statements. These
factors include the loss or expiration of patents, marketing
exclusivity or trademarks, or the risk of failure t...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.